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Abstract
Background: Chronic Fatigue Syndrome (CFS), Persian Gulf War Illness (PGI), and fibromyalgia
are overlapping symptom complexes without objective markers or known pathophysiology.
Neurological dysfunction is common. We assessed cerebrospinal fluid to find proteins that were
differentially expressed in this CFS-spectrum of illnesses compared to control subjects.
Methods: Cerebrospinal fluid specimens from 10 CFS, 10 PGI, and 10 control subjects (50 µl/
subject) were pooled into one sample per group (cohort 1). Cohort 2 of 12 control and 9 CFS
subjects had their fluids (200 µl/subject) assessed individually. After trypsin digestion, peptides were
analyzed by capillary chromatography, quadrupole-time-of-flight mass spectrometry, peptide
sequencing, bioinformatic protein identification, and statistical analysis.
Results: Pooled CFS and PGI samples shared 20 proteins that were not detectable in the pooled
control sample (cohort 1 CFS-related proteome). Multilogistic regression analysis (GLM) of cohort
2 detected 10 proteins that were shared by CFS individuals and the cohort 1 CFS-related
proteome, but were not detected in control samples. Detection of ≥1 of a select set of 5 CFS-
related proteins predicted CFS status with 80% concordance (logistic model). The proteins were
α-1-macroglobulin, amyloid precursor-like protein 1, keratin 16, orosomucoid 2 and pigment
epithelium-derived factor. Overall, 62 of 115 proteins were newly described.
Conclusion: This pilot study detected an identical set of central nervous system, innate immune
and amyloidogenic proteins in cerebrospinal fluids from two independent cohorts of subjects with
overlapping CFS, PGI and fibromyalgia. Although syndrome names and definitions were different,
the proteome and presumed pathological mechanism(s) may be shared.
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Background
The legitimacy of the diagnosis of Chronic Fatigue Syn-
drome (CFS) has been questioned because it is a symptom
complex without objective markers or known pathophys-
iology [1]. The 1994 CFS case designation criteria [2]
require severe, sudden-onset, disabling fatigue lasting >6
months and ≥ 4 of 8 minor criteria. There are no unequiv-
ocal mental, physical, or other aspects of the fatigue that
separate CFS from idiopathic, affective or physical illness-
related fatigue. The minor criteria can be clustered around
complaints of pain (headache, sore muscles, joints,
throat, and lymph nodes) and central nervous system dys-
function (concentration/memory difficulties, sleep distur-
bances, and severe exhaustion after exertion). Many of
these symptoms were shared with military personnel from
the 1990–1991 Persian Gulf War. Their syndrome was
called Persian Gulf War Illness (PGI) [3,4]. Its pathogene-
sis remains unknown, but likely represented a post-
deployment syndrome following the stresses of military
hostilities. The term Chronic Multisymptom Illness (CMI)
was introduced to describe PGI [4]. Fibromyalgia (FM) is
another closely related syndrome, but is characterized by
systemic pain and hyperalgesia (tenderness) [5-7]. These
sensations implicate dorsal horn and higher central nerv-
ous system nuclei that regulate Type C, Aδ and Aβ nocice-
ptive nerve functions.
Patients demonstrate a great deal of overlap between these
syndromes. This may not be readily apparent unless a spe-
cific effort is made to identify comorbid conditions. Each
of the current case designation criteria represents a reduc-
tionist approach to focus research on a relatively homog-
enous group of subjects [1-7]. By necessity this approach
may scrutinize only a limited aspect of the complex symp-
tomatology of these patients. The coexistence of syn-
dromes is evidenced by the large number of fibromyalgia
subjects who meet criteria for CFS and allied, visceral con-
ditions [8]. For example, dysregulated visceral nocicep-
tion [9] and mucosal function may lead to an unique
nonallergic rhinitis [10-13], noncardiac chest pain, irrita-
ble bowel syndrome, vulvodynia, and other "functional"
disorders [3,7].
An alternative to the strict reductionist focus on a single
syndrome is to thoroughly assess subjects for the wider
array of potential co-existing syndromes. This permits a
comprehensive and holistic assessment of the broad spec-
trum of symptom complexes, their presentations, and
morphogenesis from one syndrome to another over time.
This may provide a more encompassing vision for under-
standing the basis of these enigmatic conditions.
In this study, groups of subjects were recruited based on
the presence of FM, PGI, and no other syndrome (healthy
control, HC). When subjects from the FM and PGI groups
were assessed more intensively, they were found to simul-
taneously satisfy the case designation criteria for several of
the CFS, PGI, FM, irritable bowel syndrome, and other
syndromes. We hypothesized that these subjects had a
wide variety of symptom complexes, but that their indi-
vidual patterns of symptoms were the result of a shared set
of underlying pathophysiological molecular mechanisms.
For the sake of discussion in this manuscript, we applied
the title "CFS" to the overlapping syndromes afflicting our
study group. CFS was the most common individual symp-
tom complex identified in the subjects studied here.
Neurological complaints such as fatigue, pain, affective
dysfunction, and dysautonomia were unifying features of
these diverse and seemingly unrelated syndromes [1-10].
We hypothesized that central nervous system dysfunction
was the primary pathological mechanism that consoli-
dated these syndromes. We predicted that the pattern of
cerebrospinal fluid proteins found in CFS would be dis-
tinct from control subjects. The differentially expressed
CFS – related proteins may be functionally related, and
relevant to the pathogenesis of CFS and its allied syn-
dromes. As a null hypothesis, we proposed that CFS, PGI
and FM were due to unique pathogenic mechanisms. If so,
the patterns of symptoms would vary greatly depending
upon the combination of syndromes afflicting any given
individual, and there would be no significant differences
between cerebrospinal fluid proteomes of the CFS, PGI,
FM and healthy control groups.
Our proteomic hypothesis was supported by pilot studies
in other disorders. Alzheimer's disease was associated
with differential expression of the cerebrospinal fluid pro-
teins cystatin C, two β2-microglobulin isoforms, an
unknown 7.7 kDa polypeptide and a 4.8 kDa vascular
growth factor polypeptide [14]. Cerebral amyloid angiop-
athy has been associated with elevated levels of amyloid-
β, cystatin C and apolipoprotein E immunoreactive mate-
rials [15]. Temporal lobe epilepsy (S100, neuron-specific
enolase) [16], and traumatic brain injury (fibrinogen
break-down products) [17] were other examples of clini-
cally defined diseases with unique profiles of cerebrospi-
nal fluid proteins (proteomes). We predicted that a
pattern of relevant proteins would be found, rather than a
single biomarker of disease [14,18-20].
A test – retest study design was used to examine the cere-
brospinal fluid proteomes of 2 independent sets (cohorts)
of CFS and HC subjects. Different proteomic strategies
were used for sample analysis. Cohort 1 consisted of HC,
CFS [1,2], and PGI groups [3,4] (n = 10 per group). Cere-
brospinal fluids (50 µl/subject) were pooled into single
HC, CFS, and PGI specimens. The subjects in the CFS and
PGI groups had extensive symptom overlap.BMC Neurology 2005, 5:22 http://www.biomedcentral.com/1471-2377/5/22
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Cerebrospinal fluid samples were examined by reversed
phase capillary liquid chromatography – quadrupole –
time-of-flight tandem mass spectrometry (CapLC-QToF
MS/MS) [21-23]. Proteins were identified and judged to
be either qualitatively detectable, or below the lower lim-
its of detection ("absent" or undetectable). The proteins
detected in both the pooled CFS and PGI groups, but
absent from the pooled HC group, of cohort 1 defined the
"cohort 1 pooled CFS proteome". Cohort 1 was equiva-
lent to a "training" set in the test – retest study design.
Cohort 2 consisted of a different group of 12 healthy con-
trol and 9 CFS subjects who had their cerebrospinal fluids
analyzed individually (200 µl/subject). The individual
proteomes of each Cohort 2 subject was obtained. They
formed the retest or confirmatory data set for comparison
to cohort 1. The individual sets of proteomic results were
analyzed by multilinear regression to define those pro-
teins that were detected significantly more frequently in
CFS than control subjects. A limited set of proteins was
identified as the "cohort 2 CFS-related proteome".
Remarkably, these two independent assessments identi-
fied 10 proteins shared by the cohort 1 and cohort 2 CFS
proteomes and not detectable in healthy control samples.
Methods
Subjects
Volunteers meeting criteria for Persian Gulf War illness
(PGI) [4], fibromyalgia (FM) [5,6], and healthy control
subjects not meeting PGI, FM or CFS [2] criteria were
recruited from Georgetown University and Walter Reed
Army Hospital Rheumatology and Psychiatry clinics,
posters, newspaper and radio advertisements. All subjects
gave informed consent. Inclusion criteria included the
clinical diagnosis of these syndromes or their absence
(healthy controls, HC), and ages of 18 to 60 years. Gen-
eral exclusion criteria were endocrine, allergic, major psy-
chiatric, and other chronic diseases that may account for
pain, fatigue or other symptoms; medication use other
than stable doses of thyroid hormone; and disorders or
lifestyle factors that could markedly affect the hypotha-
lamic – pituitary – adrenal axis or autonomic function
(e.g. excessive caffeine, antidepressants, antihypertensive
drugs). Medications were discontinued for 3 days prior to
study. The protocol and informed consent were exten-
sively reviewed by the Institutional Review Boards of the
U.S. Department of the Army, Walter Reed Army Medical
Center, and Georgetown University (#1999-090: "Mecha-
nisms of Chronic Multisymptom Illness").
Subjective and other testing
Subjects were admitted in the evening to the Georgetown
University General Clinical Research Center. They were
intensively interviewed to identify co-morbid conditions
such as CFS [1,2] and irritable bowel syndrome (Rome I
criteria) [24,25]. Questionnaires included the Medical
Outcomes Survey Short Form 36 (SF-36) [26,27], Multidi-
mensional Fatigue Inventory [28], McGill Pain short form
[29], and the Center for Epidemiological StudiesDepres-
sion Scale (CES-D) [30,31]. Pain threshold was measured
by dolorimetry. The mean of the pressures causing painful
sensations at 18 traditional tender points were deter-
mined [5,6]. Other aspects of this study, such as standard-
ized measures of hyperalgesia, functional MRI, and
autonomic function, will be reported elsewhere.
Lumbar punctures
At 9 am on the morning after admission, lumbar punc-
tures were performed by a single anesthetist (for consist-
ency). Spinal catheters (23 G) were inserted into the L4–
L5 interspace, and 3 tubes of 3 ml of cerebrospinal fluid
collected. Fluid from the 3rd  tube was centrifuged to
remove cells, aliquoted (1 ml), aprotinin (50 KIU per ml)
added, and frozen at -80°C until analysis [32]. The bulk
of the cerebrospinal fluid was used to measure catechols,
other amine neurotransmitters and their metabolites, opi-
oids [33], corticotropin releasing hormone (CRH) [32],
neuropeptide Y (NPY) [32], and substance P by ELISA and
other methods.
Cerebrospinal fluid protein preparation
Fluid from 10 HC, 10 PGI and 10 CFS subjects (50 µl/sub-
ject) were combined into separate pooled HC, PGI and
CFS specimens (cohort 1). At a later date, fluid from 12
HC and 9 CFS subjects (200 µl/subject) were analyzed
individually (cohort 2). Proteins were precipitated by
adding an equal volume of 100% ethanol, 0.2 N acetic
acid, 0.4% sodium bisulfite, chilling at -20°C for 16 hr,
followed by centrifugation at 10,000 rpm for 30 min at
4°C [34]. Pellets were resuspended in 50 µl of 0.1 M
ammonium bicarbonate pH 7.8, then digested overnight
with a 20:1 protein:trypsin ratio (sequence modified
grade trypsin, Promega, Madison, WI).
Liquid chromatography and mass spectrometry
Aliquots (6 µl) of tryptic digests were loaded into the 10
µl loop of a Waters CapLC (Waters Corp., Milford MA
USA) [21-23]. Peptides were desalted and concentrated by
deposition in a Biobasic C18 precolumn (Thermo Hyper-
sil-Keystone, Bellefonte, PA, USA). They were then eluted
through a Zorbax C18 reverse phase column (100 µm ×
150 mm, 300 Å particle size, 5 µl volume, Micro-Tech Sci-
entific, Sunnyvale, CA). The buffer gradient began with
95% solution A (0.2% formic acid in water) and increased
to 95% solution B (0.2% formic acid in acetonitrile) at 1
µl per min for 100 min. Eluted peptides were ionized by
an electrospray device and analyzed by Q-ToF MS/MS
(Waters). The total ion current was determined for each
mass spectrometry run to confirm that similar amounts of
peptides were ionized from each sample.BMC Neurology 2005, 5:22 http://www.biomedcentral.com/1471-2377/5/22
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Peptide sequencing and protein identification
The "peak list" files (*.pkl files) of raw mass spectra for all
peptides were exported into the MASCOT® MS/MS ion
search software for protein identification using the
NCBInr protein database [35]. The following general
search parameters were used: monoisotopic molecular
masses, trypsin enzyme specificity, one missed tryptic
digestion site, Homo sapiens taxonomy, and peptide toler-
ance of ± 0.4 Da and MS/MS tolerance of ± 0.3 Da. Ions
present in many spectra (unknown shared ions and
trypsin – autopeptide digest peptides) were excluded [36].
In general, at least 2 peptides covering a minimum
sequence of 15 amino acids from unique regions of
polypeptides (i.e. not regions of sequence identity shared
by other domain or protein family members) were
required to identify a single protein [37]. When only a sin-
gle peptide was identified by MASCOT, manual sequenc-
ing was followed by screening against the Homo sapiens
entries in the NCBInr database [38] using the Protein
Information Resource (PIR) PeptideMatch BLAST algo-
rithm [39,40].
Statistical Analysis
Demographics and other variables were summarized by
means and 95% confidence intervals [41,42]. Differences
between groups were assessed by ANOVA. If significant (p
≤ 0.05), then differences between individual subsets were
assessed by two-tailed, unpaired Student's t-tests with
Bonferroni corrections for multiple comparisons.
The lists of qualitatively detected proteins from the 3
pooled HC, CFS and PGI specimens (cohort 1) were com-
pared. Proteins detected in CFS and PGI but not in HC
samples were defined as the "cohort 1 pooled CFS pro-
teome".
The individual lists of proteins detected in cohort 2 were
compared by multilinear regression (GLM) with stratifica-
tion by CFS status, gender and age. The proteins signifi-
cantly associated with CFS status ("cohort 2 CFS
proteome") were compared to the "cohort 1 pooled CFS
proteome". A step-wise multilogistic model was iteratively
created to predict CFS status for cohort 2 with maximum
concordance and the minimum number of CFS – related
proteins.
Finally, the pooled HC, CFS, and PGI results (cohort 1)
were treated as if they were from single individuals, and
collated with the cohort 2 results to compare the largest
possible number of samples. This was justified because
the pooled cohort 1 results were virtually identical to
those from the individuals of cohort 2. The frequencies of
protein detection between these compiled CFS and HC
groups ("all samples") were assessed by ANOVA (differ-
ences between means) and Fisher's Exact test (differences
in proportions) [41,42].
Results
Demographics, pain thresholds and overlapping 
syndromes
Ages were not significantly different between groups in
either cohort (table 1). There were significantly more
males in the pooled HC than pooled CFS group. There
was a high degree of overlap of the syndromes of CFS,
PGI, and FM within the pooled CFS and pooled PGI
groups, and the CFS individuals (figure 1). The cohort 1
pooled CFS group had 4/10 subjects with comorbid FM.
The cohort 1 pooled PGI group had 8/10 subjects with
comorbid CFS; half of those also had FM. The cohort 2
CFS individuals were divided equally between CFS alone,
CFS+FM and CFS+PGI. CFS was present in 27 of 29 sub-
jects, and was the most frequent individual syndrome in
cohorts 1 and 2. PGI was present in 13/29 and FM in 11/
29. This confirmed that individuals recruited for one syn-
drome also met case designation criteria for additional
syndromes as well.
SF-36 scores
The HC pooled group and HC individuals gave identical
results for all categories, indicating normal quality of life
Table 1: Demographics of Cohort 1 (pooled samples) and Cohort 2 (individual samples). Mean (95% C.I.).
Group N Age (yr) Male CESD Pain Threshold (kg)
COHORT 1 (Pooled Samples)
HC Pool 10 34.4 (29.1 to 39.7) 80% 4.3 (0.6 to 7.9) 7.69 (5.72 to 9.65)
CFS Pool 10 39.9 (34.3 to 45.5) 20% *** 17.6 *** (12.1 to 23.0) 4.01 ** (2.86 to 5.16)
PGI Pool 10 43.5 (38.7 to 48.3) 60% 18.1 ** (8.7 to 27.5) 4.89 * (3.64 to 6.14)
COHORT 2 (Individual Samples)
HC 12 41.3 (33.6 to 48.9) 75% - 7.17 (5.71 to 8.64)
CFS 9 39.1 (32.2 to 46.0) 33% - 4.97 § (3.75 to 6.19)
* p < 0.05, ** p < 0.01, *** p < 0.001 compared to HC Pool results; § p < 0.05 compared to HC individuals; ANOVA followed by Student's t-tests.BMC Neurology 2005, 5:22 http://www.biomedcentral.com/1471-2377/5/22
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Venn diagram of co-morbid, overlapping syndromes Figure 1
Venn diagram of co-morbid, overlapping syndromes. The numbers of subjects satisfying the case designation criteria for CFS, 
PGI and FM in the Cohort 1 pooled CFS and pooled PGI groups, and Cohort 2 CFS group are shown. Each group had a highly 
unique combination of these syndromes.
CFS + FM = 3  CFS + PGI = 3 
CFS only = 3 
Cohort 2, Individual CFS, n=9 
PGI + CFS + FM = 4 
PGI + CFS = 4; no FM 
PGI only = 2 
Cohort 1, Pooled PGI, n=10 
PGI = 0
CFS + FM = 4 
CFS only = 6 
Cohort 1, Pooled CFS, n=10 BMC Neurology 2005, 5:22 http://www.biomedcentral.com/1471-2377/5/22
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(scores near 100) (figure 2). The pooled CFS and PGI
groups, and CFS individuals also had equivalent scores for
each domain. Their scores for most domains were signifi-
cantly different from the respective HC scores (p < 0.02 by
ANOVA; p < 0.02 by Student's t-tests after Bonferroni cor-
rections). Exceptions were role emotional (RE), mental
health (MH) and general health change (GH∆) [26,27].
Multidimensional fatigue inventory scores
The pooled HC and HC individuals had lower scores that
trended towards normality for all domains (figure 3) [28].
Cohort 1 pooled CFS and pooled PGI scores for all
domains were significantly higher than pooled HC (p <
0.01 by t-tests). Pooled PGI had significantly higher scores
than pooled HC for general (p = 0.0001), physical (p =
0.006) and mental fatigue (p = 0.02). Cohort 2 CFS indi-
viduals had significantly higher scores than HC individu-
als for general and mental fatigue (p < 0.003).
Center for epidemiologic studies depression scale (CESD)
Scores over 16 suggest affective dysfunction [30,31].
Questionnaires were completed by the cohort 1 subjects
only. Pooled HC had normal, low scores (table 1). Scores
for the pooled CFS and CMI groups were similar to each
other, and significantly higher than HC.
Pain and tenderness
The McGill short form pain questionnaire was completed
by only 12 HC, 12 CFS and the 10 pooled PGI subjects
(table 1). Scores for CFS and PGI groups were significantly
higher than HC. Affective scores were 0.1 (-0.1 to 0.2) for
HC, 2.5 (1.6 to 3.4) for CFS, and 3.2 (1.2 to 5.2) for PGI
(p = 0.002 by ANOVA) [29]. Sensory scores had the same
trend: 1.0 (-0.3 to 2.3), 10.2 (6.4 to 13.9) and 10.2 (5.7 to
14.7), respectively (p = 0.0005 by ANOVA). Pressure-
induced pain thresholds were similar for both of the HC
groups (table 1). The pooled CFS, pooled PGI, and cohort
2 CFS individuals had significantly lower thresholds than
their respective controls. This was consistent with the
admixture of FM subjects who have sensory hyperalgesia
("tenderness") and pain complaints [5,6].
Irritable bowel syndrome
About half of all the CFS and PGI subjects had irritable
bowel syndrome (Rome I criteria) [24] compared to none
of the HC (p = 0.002 by ANOVA).
Clinical summary
The pooled HC and HC individuals had virtually identical
demographic, pain threshold, and psychometric results.
The variances for the pooled HC results were small indi-
SF-36 scores for each group (mean ± 95% C.I.) Figure 2
SF-36 scores for each group (mean ± 95% C.I.). Physical Function (PF), Social Function (SF), Role Physical (RP), Role Emotional 
(RE), Mental Health (MH), Vitality (Vit), Pain, General Health Perception (GH-P) and General Health Change (GH∆) were iden-
tical for the set of pooled (Cohort 1; yellow bars) and individual (Cohort 2; beige bars) HC subjects. These domains were also 
identical for the set of pooled CFS (light blue bars), pooled PGI (light purple bars) and CFS individuals (teal bars). Significant dif-
ferences between these datasets were found for all indicators except RE, MH and GP∆ (p < 0.02 by ANOVA).BMC Neurology 2005, 5:22 http://www.biomedcentral.com/1471-2377/5/22
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cating homogeneity regardless of age or gender. Results
for cohort 1 CFS and PGI, and cohort 2 CFS subjects were
essentially equivalent. Scores were generally significantly
different from their HC comparison groups. There was a
surprising similarity even though the proportions of sub-
jects with each case designation criteria in each cohort
were different. This supported our hypothesis that the des-
ignation of CFS, PGI or FM was overruled by the overlap-
ping nature of these syndromes, and that a shared
mechanism may have been present. Comparisons of the
cerebrospinal fluid proteomes tested this hypothesis.
Proteomics of cohort 1
Mass spectrometry and bioinformatics analysis identified
17 proteins in the pooled HC group, 63 in the pooled CFS
and 40 in the pooled PGI samples (table 2). A total of 73
unique proteins were identified. Twelve were detected in
all three pools. The pooled CFS and PGI samples shared
20 proteins that were not detected in the pooled HC
group. This formed the "cohort 1 pooled CFS proteome"
(table 3, column 2). The most pertinent of these matched
proteins had probable origins in plasma or the central
nervous system. Probable plasma proteins were the anti-
proteases α-2-macroglobulin (α-2-mac) and α-1-antichy-
motrypsin; the metal transport and antioxidant proteins
ceruloplasmin (ferroxidase II), haptoglobin and oroso-
mucoid 2 (ORM2; α1-acid glycoprotein, type 2); and
complement factors C3 and the C4A and C4B gene prod-
ucts. Brain – derived proteins included amyloid β (A4)
precursor like protein 1 (APLP1), autotaxin (ENNP2, ecto-
nucleotide pyrophosphatase/phosphodiesterase 2, phos-
phodiesterase I/nucleotide pyrophosphatase 2; alkaline
phosphodiesterase I), carnosine dipeptidase 1 (CNDP1,
carnosinase 1, CN1), and pigment epithelium-derived
factor (PEDF). BEHAB (brain enriched hyaluronan bind-
ing protein, brain specific chondroitin sulfate proteogly-
can, brevican) and gelsolin were structural proteins. The
numbers of proteins detected in each of the 3 pooled sam-
ple were proportional to the total ion current for HC
(7,000), PGI (26,000) and CFS (33,600) (R2 = 0.94). This
raised the possibility that there was less protein in the
pooled HC sample or a smaller amount of tryptic peptides
Multidimensional fatigue inventory scores (mean ± 95% C.I.) Figure 3
Multidimensional fatigue inventory scores (mean ± 95% C.I.). The healthy control (HC) pooled group (yellow  bars) and indi-
viduals (beige bars) had lower scores for all categories than the pooled CFS (light blue bars), pooled PGI (light purple bars), and 
CFS individuals (teal bars) (p < 0.03 by ANOVA). The categories, from left to right, were general fatigue, physical fatigue, 
reduced activity, reduced motivation, and mental fatigue.BMC Neurology 2005, 5:22 http://www.biomedcentral.com/1471-2377/5/22
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were loaded during mass spectrometry than for the
pooled CFS and CFS and PGI specimens. These possibili-
ties were examined in cohort 2.
Proteomics of cohort 2
The 21 individual samples from cohort 2 contained 113
distinct proteins (table 2). The HC individuals had a
cumulative total of 71 proteins, including 32 found only
in this group. The 12 HC samples contained an average of
16.3 (14.4 to 18.3), and generated an average total ion
current of 17,800 (13,500 to 23,400). There were 39 pro-
teins shared between the two groups in this cohort. CFS
subjects had a total of 82 proteins identified. There were
43 proteins found only in CFS. The 9 CFS samples had an
average of 23.3 (12.6 to 34.0) proteins per subject, and
total ion current of 21,200 (12,800 to 34,900). Since the
numbers of proteins detected and total ion currents were
not different between the HC and CFS samples, it was
likely that the cerebrospinal fluid total protein concentra-
tions were similar. The low number of proteins detected
for HC in cohort 1 may have been due to dilution during
sample mixing, trypsin digestion or loading for mass spec-
trometry.
Multilinear regression by general linear modeling (GLM)
identified 16 proteins from the cohort 2 CFS samples that
Table 4: Multilinear regression (general linear model; GLM) analysis of the cohort 2 CFS – associated proteome. Proteins that were 
detected significantly more frequently in CFS than HC were shown in column 2. The significance (P), explained variance (R2), and 
probabilities for the association of each protein when stratified by CFS status, gender, and their cross-product were tabulated. The 
presence of at least 1 of the 5 CFS proteome proteins (right justified and bold italics) was sufficient to identify all the CFS subjects in 
Cohort 2 (B1/5; see Results). (n.s., not significant).
Cohort 2: Multilinear Analysis (GLM; individual samples)
GeneID Cohort 2 CFS Proteome PR 2 CFS Gender CFS × Gender
3868 Keratin 16 (B1/5) 0.0001 1 0.0001 0.0001 0.0001
2 α2-Macroglobulin (B1/5) 0.001 0.63 0.009 0.023 0.003
1356 Ceruloplasmin 0.001 0.63 0.009 0.023 0.003
5005 Orosomucoid 2 (B1/5) 0.001 0.63 0.009 0.023 0.003
5168 Autotaxin (B1/5) 0.001 0.63 0.009 0.023 0.003
351 APLP1 0.001 0.63 0.009 0.023 0.003
63827 BEHAB 0.001 0.63 0.009 0.023 0.003
140446 Keratin 6C 0.001 0.63 0.009 0.023 0.003
3872 Keratin 17 0.001 0.63 0.009 0.023 0.003
5004 Orosomucoid 1 0.001 0.63 0.009 0.023 0.003
3858 Keratin 10 0.013 0.48 n.s. 0.016 n.s.
721 C4B 0.022 0.44 0.007 n.s. n.s.
5176 PEDF (B1/5) 0.022 0.44 0.007 n.s. n.s.
2934 Gelsolin 0.033 0.41 n.s. n.s. 0.011
84735 CNDP 1 0.037 0.40 n.s. 0.033 n.s.
3861 Keratin 14 0.037 0.40 n.s. 0.033 n.s.
Table 2: Yields of proteins identified in each cohort and group. A total of 73 proteins were identified from the 3 pooled HC, CFS and 
PGI specimens of cohort 1. Twenty proteins were shared by the CFS and PGI specimens that were absent from the pooled HC 
sample. This was the cohort 1 pooled CFS – related proteome. Cohort 2 consisted of 12 HC and 9 CFS individuals. A total of 113 
proteins were identified, with 16 identified by multilinear regression (general linear model, GLM) as the cohort 2 CFS – related 
proteome. When the proteins from all of the specimens were examined, a set of 19 out of 115 proteins were significantly different 
between HC and CFS by ANOVA.
Cohort 1 (pooled samples) Cohort 2 (individual samples) All specimens
Protein yield per cohort 73 113 115
Groups in each cohort HC CFS PGI HC CFS HC CFC
Samples per group 1 1 1 12 9 13 11
Proteins per group 17 63 40 71 82 72 83
Proteins shared within cohorts 12 12 12 39 39 40 40
Proteins unique to each group 2 28 8 32 43 32 43
CFS-related proteomes 20 16 19
Statistical method Matching GLM ANOVABMC Neurology 2005, 5:22 http://www.biomedcentral.com/1471-2377/5/22
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were not detectable in the individual HC samples (table
4). Ten of these sixteen proteins were also detected in the
"cohort 1 pooled CFS proteome" (table 3). This degree of
protein matching between two independent populations
of CFS subjects was highly unlikely to be a random event
(odds <10-15).
α2-Mac, ceruloplasmin (figure 4), ORM2, and autotaxin
were significantly associated with CFS status and gender
(table 4). These were also present in the cohort 1 pooled
CFS proteome. APLP1, BEHAB, orosomucoid 1 (ORM1,
α1-acid glycoprotein, type 1), and keratins 6C and 17
were also associated with CFS and gender. Keratins 16
(K16), 14 and 10 were associated with male gender (table
4). Other gender-related factors may be found in future
surveys given the female predominance (80%) of CFS
[1,2].
PEDF and C4 were significantly associated with CFS but
not to gender (table 4). C4 has 2 genes, C4A and C4B,
with the latter more significantly associated with CFS. Gel-
solin was associated with CFS status. CNDP1 was origi-
nally identified as glutamate carboxypeptidase-like
protein 1, but was correctly assigned using PIR website
tools [39,40]. All of these proteins were detected in both
the cohort 1 pooled CFS and cohort 2 CFS proteomes.
Predictive statistical model for CFS from cohort 2
Multilogistic analysis demonstrated that a smaller set of 5
proteins could identify all of the cohort 2 CFS subjects.
They were α-2-mac, APLP1, K16, OMD2, and PEDF. Sub-
jects who had detectable levels of at least 1 out of these 5
proteins had an odds ratio of 34.5 in favor of having CFS
regardless of gender (1.49 to 809.61; p = 0.0072, Fisher's
Exact test). This new "biosignature" variable of having ≥1
out of 5 proteins present in the cerebrospinal fluid was
defined as B1/5. It was included in a logistic model to pre-
dict CFS status for the 21 subjects in cohort 2:
CFS status = gender + (B1/5)
The model was significant (converged asymptotically)
and had a concordance rate of 80%. To our knowledge,
this is the first model to predict CFS status based solely on
objective data.
Factor analysis of cohort 2
The syndromic designations, results of the questionnaire
and psychometric tests, and components of the proteomic
studies were analyzed. No significant factors were identi-
fied. This suggested that the cerebrospinal fluid proteome
was independent of the exact spectrum of complaints and
self-reported symptoms found in the CFS spectrum of ill-
Table 3: Chronic fatigue syndrome – associated cerebrospinal fluid proteomes. Proteins from the cohort 1 – and cohort 2 – related 
CFS proteomes (+) or not part of these proteomes (0) were shown in columns 2 and 3. The 5 proteins from cohort 2 that were most 
predictive of CFS (80% concordance) were defined by the "biosignature variable"B1/5(right justified and bold italics). The 2 cohorts were 
combined (n = 24 samples) and the frequencies of detection in all control (HC, n = 13) and CFS (n = 11) samples compared by ANOVA 
and Fisher's Exact Test. NCBI accession numbers (gi|) were given.
Cohort CFS – Associated Proteome (all 24 samples) HC % (n = 13) CFS % (n = 11) ANOVA Fisher's Exact Test
GeneID
12
720, 721 + + Complement C4A/B 0% 55% 0.0010 0.0034
2934 + + Gelsolin 0% 45% 0.0046 0.011
3868 0 + Keratin 16 (B1/5) 0% 45% 0.0046 0.011
5176 + + PEDF (B1/5) 0% 45% 0.0046 0.011
3537 00 Ig λ 15% 64% 0.014 n.s.
351 + + APLP1 0% 36% 0.016 0.031
1356 + + Ceruloplasmin 0% 36% 0.016 0.031
2+ + α-2-Macroglobulin (B1/5) 0% 36% 0.016 0.031
5005 + + Orosomucoid 2 (B1/5) 0% 36% 0.016 0.031
5168 + + Autotaxin 0% 36% 0.016 0.031
1114 00 Chromogranin B 0% 36% 0.016 0.031
63827 + + BEHAB (B1/5) 0% 36% 0.016 0.031
12 + 0 α-1-Antichymotrypsin 8% 45% 0.034 n.s.
3240 + 0 Haptoglobin 15% 55% 0.044 n.s.
3263 00 Hemopexin 15% 55% 0.044 n.s.
6696 00 Secreted phosphoprotein 1 0% 27% 0.046 n.s.
3872 0 + Keratin 17 0% 27% 0.046 n.s.
140446 0 + Keratin 6C 0% 27% 0.046 n.s.
718 + 0 Complement C3 23% 64% 0.047 n.s.BMC Neurology 2005, 5:22 http://www.biomedcentral.com/1471-2377/5/22
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nesses (figure 1). The CFS – associated proteome and B1/5
were consistent with our hypothesis that a common path-
ological mechanism was shared by these allied syn-
dromes, and was independent of the set of symptoms
expressed by each individual.
Combination of all samples
Because of the congruent proteomes from the pooled and
individual samples, data from cohorts 1 and 2 were com-
bined for further analyses (n = 24 total samples). A total
of 115 unique proteins were detected (table 2). HC had 72
proteins and CFS 83. These groups shared 40 proteins. A
set of 44 proteins were detected at low frequency in only
1 or 2 subjects from one group or the other. The frequen-
cies of detection of shared proteins were highly correlated
between the 2 groups of subjects (figure 5). The slope of
the regression line was 0.93, the intercept 0.05, and R2 =
0.70.
CFS – related proteome from all samples
Nineteen proteins were detected significantly more fre-
quently in CFS than HC samples (p < 0.05 by ANOVA)
(table 3). Chance would predict that as many as 1 out of
20 proteins may have been shared by the two proteomes
(p = 0.05). However, detection of 19/115 (0.165) sug-
gested that nonrandom pathological processes were active
in generating the CFS proteome. The 19 CFS – related pro-
teins were shifted upwards from the line of identity shown
on figure 5. The proteins were detected in 27% to 64% of
CFS, and 0% to 23% of HC samples. Fisher's Exact test was
significant for 16 of these proteins (table 3).
Nine proteins were found consistently in cohorts 1 and 2
and the combined sample (table 3). Plasma proteins
included α-2-mac, ceruloplasmin, ORM2, and C4A/C4B.
Brain – derived proteins were APLP1, autotaxin, PEDF and
the structural proteins BEHAB and gelsolin. Cohort 2 and
the total sample showed significant differences between
CFS and HC for keratin proteins K6C, K16 and K17. Con-
versely, cohort 1 and the combined group both detected
C3, α-1-antichymotrypsin, and haptoglobin significantly
more frequently in CFS than HC. The combined group of
24 samples produced 4 proteins that were not signifi-
cantly different between CFS and HC in the smaller
cohorts 1 and 2. Hemopexin was probably from plasma.
Ig  λ was likely a marker of plasma immunoglobulin
influx, although local B lymphocyte synthesis was possi-
ble. Significant brain – derived polypeptides were chrom-
ogranin B and secreted phosphoprotein 1 (osteopontin).
Seven proteins were significantly different by ANOVA but
not Fisher's Exact test. The larger overall group size (n =
24) was responsible for the differences in statistical signif-
icance compared to cohort 2 (n = 21).
Fourteen of the proteins were not detected in HC samples
(0% detection) (table 3). They may have been present in
HC at levels below the lower limit of detection of the mass
spectrometer. Future qualitative studies starting with
larger amounts of cerebrospinal fluid protein may identify
these proteins in HC subjects. Quantitative studies will be
required to determine if concentrations were different
between CFS and HC. These could not be performed here
because of the insufficient volumes of cerebrospinal fluid
that remained. These findings suggest that additional
samples may have increased the size of the CFS – related
proteome detected by MS-MS.
Shared cerebrospinal fluid proteome from all samples
The 16 most prevalent proteins (frequencies of detection
≥ 50%) had both plasma and central nervous system ori-
Ceruloplasmin (ferroxidase II) peptide mass spectrogram Figure 4
Ceruloplasmin (ferroxidase II) peptide mass spectrogram. This sequencing data was shown for the time-of-flight mass spec-
trometer (ToF, 2nd MS). The relative signal intensities for each fragment of the ceruloplasmin peptide (y-axis) were plotted 
against mass/charge (m/z; x-axis). The peptide, GVYSSDVFDIFPGTYQTLEMFPR, was sequenced from the y-series (right to 
left; N-terminal to C-terminal). It had m/z = 890.41 and z = 3+, for a mass of 2671.23.
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gins ' [see Additional file 1]'. Albumin, Ig γ1, Ig γ4, trans-
ferrin,  α-1-antitrypsin and the apolipoproteins E
(including isotypes 3 and 4), J, and A-I were probably of
plasma origin. Prostaglandin D2 synthase, transthyretin,
and angiotensinogen were of brain origin. Dickkopf
related protein-3 likely inhibited neural growth in these
adult brains. The precise targets of leptomeningeal cysta-
tin C were unclear, but its high frequency of detection
highlighted the importance of secreted cysteine protease
inhibitors in normal central nervous system function. Epi-
thelial cells of the choroid plexus or arachnoid mem-
branes were the probable sources of the keratins.
Epidermal contamination with keratins 1, 9 and 10 dur-
ing the lumbar punctures or processing could not be ruled
out ' [see Additional file 1]'.
Plasma proteins detected with frequencies of 25% to 49%
included hemoglobins, immunoglobulin chains, and oro-
somucoid 1 ' [see Additional file 1]'. Structural proteins
(tubulins, keratins, actin β, and secreted phosphoprotein
1) were common. The latter was associated with CFS. Reg-
ulatory proteins included chromogranin A and the neu-
ron directional marker disco-interacting protein 2
[Drosophila] (DIP2). Many of the proteins had multiple
domains and may have had additional functions in vivo.
A large number of proteins were detected in 3 or fewer
samples ' [see Additional file 1]'. This was apparent by
converting figure 5 into a 3 – dimensional plot showing
the numbers of proteins detected in the HC and CFS
groups (figure 6). Discrete ranges of frequencies ("bins")
were selected. The seven bins were 0, increments of 15%
up to 75%, and the upper 25%. The bins generated a grid
that was analogous to figure 5. The vertical axis showed
the percentages of total proteins that were present at each
intersection point on the grid. Most of the proteins were
grouped in the low frequency intersection points (<30%
detection in both groups). A small number of cerebrospi-
nal fluid proteins with known high concentration were
detected in most samples. These shared proteins extended
the line of identity to near the 100% detection point. The
high concentrations of this small set of proteins provided
the rationale for removing these proteins in order to assess
lower abundance proteins. The CFS – associated pro-
teome was identified along the 0%, 1 to 15%, and 16 to
30% HC grids, and the 31% to 75% grids of the CFS group
(figure 6).
Novel proteins from all samples
Overall, 62 of the 115 proteins had not been detected in
previous studies of cerebrospinal fluid ' [see Additional
file 1]'. These included DIP2, neuronal PAS domain pro-
tein 2 (seasonal affective disorder – related), additional
sex combs – like protein 1 (ASXL1), and neuroglobin. Sev-
eral were represented by only a single, highly selective
peptide. Keratins 5, 6c, 6e, 14, 16, and 17 were the largest
single protein family to be newly described.
Depiction as a two-dimensional electrophoresis gel
The proteins from the HC and CFS groups were graphed
based on predicted molecular weights and isoelectric
points (figure 7) ' [see Additional file 1]'. The cerebrospi-
nal fluid proteins, including the CFS – associated proteins,
were most concentrated between isoelectric points of 4.7
and 7, and molecular weights of 30 to 110 kDa. The
shared proteins appeared as coincident circles (HC)
within squares (CFS). The proteins significantly associ-
ated with CFS (p < 0.05 compared to HC for frequency of
detection) had molecular weights between 25 kDa and
110 kDa. They fell into 2 groups. Five proteins were
detected in over half of CFS samples, and had pI's between
6 and 7. Twelve CFS – related proteins were detected in
26% to 50% of CFS samples and had pI's between about
4.5 and 6.
Discussion
The discovery of shared cerebrospinal fluid proteins
between two independent cohorts of CFS subjects that
were not present in two independent sets of healthy con-
trol subjects demonstrated that there was differential pro-
tein expression in this syndrome (table 3). There was
significant overlap of CFS, PGI and FM syndromes within
the CFS group (figure 1). The mix of co-morbid syn-
The correlation between the frequencies of protein detec- tion in the CFS (black triangles) and HC (open circles)  groups were shown Figure 5
The correlation between the frequencies of protein detec-
tion in the CFS (black triangles) and HC (open circles) 
groups were shown. Nineteen proteins were detected signif-
icantly more frequently in the CFS than HC group (p ≤ 0.05 
by ANOVA). These CFS – associated proteins were shifted 
away from the line of identity. This line demonstrated the 
high correlation of detection frequencies between the CFS 
and HC samples for the remaining 98 proteins (R2 = 0.70).
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dromes was different for cohorts 1 and 2, yet the pro-
teomic studies identified a single CFS – related proteome.
Both the individual proteins and the patterns of proteins
may offer insights into CFS pathophysiology, and serve as
potential biomarkers for CFS diagnosis and the assess-
ment of disease severity. The variable B1/5 epitomized the
qualitative pattern recognition of this proteomic "biosig-
nature". The statistical model was predictive of CFS status
regardless of which of the 5 proteins, or how many of
them, were detected. Prospective studies will be required
to determine the sensitivity, and specificity of the pro-
teomic pattern and optimal logistic model(s) for discrim-
inating CFS and related syndromes from normal,
idiopathic fatigue, illness-related fatigue states, affective
disorder, chronic pain states such as fibromyalgia and
regional pain syndromes, and inflammatory central nerv-
ous system disorders [1-7]. These studies of larger num-
bers of subjects would be anticipated to refine the CFS –
related proteome and the terms of the biosignature varia-
ble. These prospective studies are also required to test the
objective nature of biosignature variable and other CFS –
related proteins for predicting CFS status.
The basis for differences between CFS and HC was the
ability of the mass spectrometer to detect certain proteins
in CFS but not HC. This concept of "detectability" is criti-
cal to understanding the qualitative nature of our results
and predictive model. Improvements in the lower limits
of detection may identify a larger number of low abun-
dance proteins. These may include the cerebrospinal fluid
proteins that were relatively more abundant (and detecta-
ble) in CFS compared to HC subjects. This remains to be
tested. Quantitative studies will be required to confirm
the qualitative distinctions between the CFS and HC
groups.
The origins and putative functions of the CFS – related
proteome may provide clues to CFS pathophysiology.
Cerebrospinal fluid is generated by (a) selective diffusion
and transport of plasma components through the choroid
plexus and brain parenchymal vessels, (b) synthesis by the
choroid plexus and meningeal epithelia, (c) secretion
from brain neuron, glia, and other parenchymal cells into
the local interstitial fluid, and (d) release from injured
and apoptotic parenchymal, mucosal and leukocytic cells
[43]. Plasma protein flux is regulated by transport through
the blood-brain barrier and the efflux of protein from cer-
ebrospinal fluid through arachnoid granulations into
venous blood [43,44]. Alternatively, the fluid may exit the
meningeal space through perinasal and olfactory lym-
phatics [45]. Dysfunction of hydrodynamic plasma influx
or cerebrospinal fluid efflux may contribute to the varia-
tions in relative detectability of brain versus plasma pro-
teins in the CFS proteome [46]. Decreased plasma influx
would lead to relatively higher abundances of proteins
synthesized in the brain. These proteins may have become
easier to detect in CFS. Brain parenchymal mast cells may
regulate brain microvascular permeability, possibly
through histamine release [47]. If so, this could explain
the benefits of tricyclic drugs such as doxepin and imi-
pramine that have potent histamine receptor 1 antagonist
activities [48]. Histamine receptor 1 antagonists that do
not cross the blood brain barrier have no benefit in CFS
[49].
Proteins of plasma, choroid plexus, or meningeal origin
included α-2-mac [50], orosomucoid 1 and 2 [51], α1-
antichymotrypsin [52], complement factor 4B precursor
[53], and ceruloplasmin [54]. These antiproteases, anti-
oxidant, pro- and anti-inflammatory proteins suggested
activation of the cerebrospinal innate immune system.
Secreted central nervous system proteins included PEDF
[55], CNDP1 [54], and autotaxin [56].
ORM2 is a glycosylated plasma lipocalin with a hydro-
phobic pocket that binds a wide variety of drugs, hemin,
progesterone and the CCR5 receptor on macrophage –
lineage cells [57,58]. Both ORM2 and ORM1 are acute
Distributions of proteins in healthy control (HC) and CFS  samples Figure 6
Distributions of proteins in healthy control (HC) and CFS 
samples. The frequency of detection for each protein was 
determined for the HC (left axis) and CFS (right axis) groups. 
These axes were divided into "bins" of 0% (absent), 1 to 15%, 
16 to 30%, 31 to 45%, 46 to 60%, 61 to 75%, and 76 to 100%. 
The vertical axis was the percentage of all proteins detected 
within each intersection of the CFS vs. HC matrix. Most of 
the proteins were detected in less than 30% of each group. 
Proteins detected in both groups with roughly equal frequen-
cies of detection were near the line of identity (white bars). 
The grid region corresponding to the CFS – associated pro-
teome was highlighted by black bars.
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phase reactants that are synthesized in the liver, but may
also be synthesized at sites of brain injury or astroglial cell
activation [59]. Like haptoglobin [60] and hemopexin
[61], ORM2 and ORM1 may contribute to heme and iron
sequestration in the central nervous system in CFS. Iron
sequestration is an important antioxidant and antibacte-
rial innate immune defense function [62]. Haptoglobin
and apolipoprotein J act as extracellular chaperone pro-
teins  in vivo [63]. They may exert anti-inflammatory
actions by inhibiting the inappropriate self-association of
"damaged" (misfolded) extracellular proteins.
The presence of heme sequestering proteins begged the
question of whether free hemoglobin was present in cere-
brospinal fluid. This was the case since hemoglobins α1
and α2, β, β Sickle, and δ were detected in the cerebrospi-
nal fluid proteome shared by all subjects ' [see Additional
file 1]'. The source of hemoglobin in normal cerebrospi-
nal fluid could have been the lumbar puncture. If so, the
detection rate for hemoglobin would be expected to be
similar for all groups, as was found. However, this did not
explain the significantly more frequent detection of heme
scavengers in CFS (55%) compared to HC (15%) samples
(table 3). Apolipoprotein B has been used as a marker for
the acute introduction of plasma into the cerebrospinal
fluid since this protein is not synthesized in the brain [64].
Apolipoprotein B was detected only once (CFS) ' [see
Additional file 1]', indicating that the lumbar punctures
were not a consistent cause of hemorrhage [64]. Free
hemoglobin levels (and mass spectrometric detection)
may be related to haptoglobin isoforms [65]. We have not
evaluated this potential correlation in our population.
A number of central nervous system conditions may lead
to localized bleeding with hemoglobin release with the
induction of heme sequestering proteins. One large group
meeting these characteristics are the cerebral amyloid
angiopathies (CAA) (cerebrovascular amyloidosis) [66].
CAA syndromes are defined by protein misfolding,
perivascular amyloid deposition, weakening of vessels
walls, microhemorrhages to severe cerebral infarction,
and dementia or sudden death occurring in the 3rd to 5th
Isoelectric point (pI) vs Figure 7
Isoelectric point (pI) vs. logarithm of molecular weight. The frequencies of detection for proteins in the healthy control (HC) 
group were graded as 1 to 25% (small circles), 26 to 50% and 51 to 100% (large circles). Proteins detected in the CFS group 
(open squares) were similarly graded. The CFS – associated proteins detected in 26 to 50% and 51 to 100% of samples were 
depicted as smaller and larger grey squares, respectively.
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decades. The CFS spectrum of illnesses do not demon-
strate higher than normal rates of these causes of death
making it unlikely that any of the currently identified CAA
syndromes were responsible. However, we hypothesize
that a mild, focally transient or reversible form that does
not lead to either permanently damaging or lethal hemor-
rhage or dementia may occur in CFS.
This hypothesis would explain many of the parallels
between the proteins associated with CAA syndromes and
the CFS – related proteome. Gelsolin is an actin "capping"
protein that terminates actin polymerization [67]. Gelso-
lin cleaved by capsase-3 leads to the "blebbing" during
apoptosis. Mutant gelsolin isoforms lead to misfolding
and the perivascular amyloid fibril deposition in Finnish
type cerebrovascular amyloidosis [66,68]. Gelsolin amino
acid sequences 173–243 and 173–202 are α-helices that
are converted to β – pleated sheet conformations in amy-
loidosis [68]. The proteases responsible for the gelsolin
cleavage that permit the change in secondary structure are
unknown. An E693Q mutation in amyloid β (A4) precur-
sor-like protein 1 (APLP1) leads to hereditary Dutch type
– cerebral hemorrhage with amyloidosis ' [see Additional
file 1]' [69]. This is separate from the involvement of this
protein in Alzheimer's disease. Immunoglobulin lambda
(Ig λ) light chains are relatively unstable, have a tendency
to unfold and polymerize [70], and have been associated
with APLP1 in an intracerebral syndrome [71], and sys-
temic amyloid syndromes with and without B lymphocyte
dyscrasias [72].
Cystatin C, a leptomeningeal inhibitor of papain – like
cysteine proteases, was found in HC and CFS samples.
Cystatin C is a homodimer with several domains. The ran-
dom coil polypeptide linking the terminal domain to the
rest of the protein can be proteolytically cleaved [73]. The
"free" domains refold their tertiary structure from con-
strained α – helices to β – pleated sheets with lower free
energies [74]. These domains are then reattached to the
opposite member of the homodimer. This "protein swap-
ping" mechanism is analogous to a DNA recombination –
like process [73]. Inactive β – pleated sheet domains may
then polymerize into amyloid deposits. Autosomal dom-
inant Icelandic CAA is due to the disease-causing L68Q
variant of human cystatin C [75]. Cystatin C amyloid
immunoreactive material has been found in cerebral cor-
tical, white matter parenchymal and leptomeningeal ves-
sels [74]. Deposition was more prominent in the media of
parenchymal vessels and in the adventitia of leptomenin-
geal vessels. Complexes of cystatin C or Ig λ with APLP1
have been found in extracellular deposits.
Transthyretin, a thyroxine transporting member of the
albumin family, was a common brain – derived compo-
nent of cerebrospinal fluid that was not part of the CFS
proteome ' [see Additional file 1]'. Misfolding of transthy-
retin (meningovascular amyloidosis), angiotensinogen,
β2 – microglobulin, lysozyme, the Notch3 gene product,
and the familial prion protein may each lead to amyloido-
sis [66,74,76-78]. Acquired prion diseases may potentially
contribute to the CFS – spectrum of illnesses, but the pre-
dilection for females and other epidiomological findings
make this an unlikely pathological event.
Other components of the CFS – related proteome pro-
mote amyloid deposition. Complement factors C3, C4
and B become activated in amyloidosis and Alzheimer's
disease [79]. Apolipoproteins E, E4, and J, and microtu-
bule-associated protein 2 have been associated with CAA
syndromes and Alzheimer's disease [66,80]. Apolipopro-
tein E4 may target the amyloid to vessel walls. Chrom-
ogranin B – immunoreactive material (table 3) was found
in 15% of plaques in Alzheimer's disease [81]. There was
a significant loss of chromogranin B – immunoreactivity
in the dorsolateral, the entorhinal, and orbitofrontal cor-
tex in Alzheimer's disease. The absence of chromogranin
B in these anatomical locations could result in defective
synaptic function and the loss of neurohormonal effects.
Chromogranin B – immunoreactive material was selec-
tively associated with prion protein deposits in Creut-
zfeldt-Jakob disease. In contrast, chromogranin A was
seen only in amyloid β plaques of Alzheimer's disease
[82].
Chromogranin B is a highly multifunctional protein. It is
a high capacity, low affinity calcium (Ca2+) storage pro-
tein that complexes to the inositol 1,4,5-trisphosphate
receptor (InsP3R) in the endoplasmic reticulum. Thus,
chromogranin B may modulate Ca2+ release [83]. Chrom-
ogranin B (CGB) is a prohormone that can be cleaved to
release secretogranin I precursor (Sg1), GAWK and CCB
peptides. Both chromogranins B and A are prohormones
for the antimicrobial peptides vasostatin-1 and secretoly-
tin [84]. mRNA for chromogranin B was detected in
human monocytes, and may be present in other macro-
phage/monocytic lineages such as astroglial cells in the
brain.
Pigment epithelium-derived factor (PEDF) (table 3) is
another multipurpose CNS protein [55,85]. Although a
member of the serpin (serine antiprotease) protein fam-
ily, it does not possess this activity. PEDF has antiang-
iogenic activity that may prevent or reduce
neovascularization after retinal or cerebral hemorrhage.
Both PEDF and a 44 amino acid long proteolytic fragment
have potent anti-vascular permeability effects [86]. PEDF
controls the transit of neurons through the cell cycle, pro-
moting their entry into a quiescent state [87]. The protein
may protect neurons and potentially glial cells from apop-
tosis. Protein levels in the eye and brain decrease with age,BMC Neurology 2005, 5:22 http://www.biomedcentral.com/1471-2377/5/22
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but this cannot explain the increase in detection rate in
CFS since age was not significantly different between
groups. Dickkopf-3, another protein that limits neural
proliferation [88], was detected in 46% of samples.
Autotaxin (TEFLSNYLTNVDDITLVPGTLGR) is a 23
amino acid peptide cleaved from the middle of ectonucle-
otide pyrophosphatase/phosphodiesterase 2 (ENPP2
gene) [56,89,90]. The parent protein possesses both
nucleotide pyrophosphatase and lysophospholipase D
(lyso-LPD) activities [56,91]. Aliases include phosphodi-
esterase-1α, phosphodiesterase I/nucleotide pyrophos-
phatase 2, and alkaline phosphodiesterase I. This "tumor
mobility peptide" enhances metastasis of breast and other
cancer [91]. Its unclear if the pyrophosphatase, lysophos-
pholipase D, or autotaxin functions are more important
in the brain and in CFS.
Chromogranin B, PEDF, autotaxin, angiotensinogen, and
other polypeptides are significant prohormones. The pro-
tease cascades that lead to their cleavage and the release of
active neuropeptides are poorly understood. However, the
peptide hormone effects must be potent since plasma and
brain – derived protease inhibitors were detected more
frequently in CMI than in HC (table 4).
α2-Macroglobulin [92] and α-1-antichymotrypsin were
detected in the CFS proteome (table 3). IL-1 may induce a
mutant promoter allele of α-1-antichymotrypsin that
leads to increased central nervous system and the promo-
tion of Alzheimer disease [93]. Angiotensinogen also has
serine protease inhibitor properties. Angiotensinogen was
detected in about half of all samples and was not associ-
ated with CFS. Haplotype B may be related to microangi-
opathy – related cerebral damage (MARCD) that can lead
to cognitive impairment and gait disturbances in the eld-
erly [78]. This protein is synthesized by glial cells [94,95].
The C-terminal has serine protease inhibitor activity that
inhibits angiogenesis. Angiotensins I, II and III are cleaved
from the N-terminal. Angiotensin II and III may bind to
angiotensin 4 receptors (also known as insulin-regulated
aminopeptidase [94]) in hypothalamic and brainstem
nuclei to stimulate the sympathetic nervous system
(increase systemic blood pressure), sodium and thermal
regulation. The remaining 97% (des [Ang I]angiotensino-
gen) has no assigned function.
The presence of keratin 16 suggests dysfunction in the lep-
tomeningeal and choroid plexus epithelial system in CFS.
Keratin expression in the central nervous system has been
incompletely studied, with most of the focus placed on
neoplastic tissues [96-98]. Keratin 16 is upregulated in
epidermal diseases such as psoriasis [99]. Epidermal
growth factor, interferon-γ and ras can stimulate Sp1 and
jun (AP1) proteins that activate the keratin 16 promoter.
By analogy, we hypothesize that the presence of keratin 16
in the CFS – associated proteome was an indication of epi-
thelial cell activation within the central nervous system in
CFS.
BEHAB may play a role in central nervous system repair or
remodeling processes [100]. Its 2 isoforms bind to extra-
cellular matrix hyaluronan. The full length isoform is
secreted into the extracellular matrix. The shorter, splice
variant may be linked to glycophosphatidylinositol and
form a cell surface protein. The longer variant is highly
expressed in childhood, then reaches low, steady state cer-
ebrospinal fluid concentrations by age 20. The shorter var-
iant maintains uniformly low levels throughout
development. BEHAB mRNA is elevated 7-fold in gliomas
suggesting that glial cells are the normal source in vivo.
BEHAB is also increased in response to brain injury. Glial
or other cells with BEHAB anchored to their external
plasma membranes may be attracted to putative areas of
tissue injury where extracellular matrix became exposed,
or where hyaluronan was secreted.
An alternative to the CAA hypothesis is glial cell activation
[101] with the release of innate immune and regulatory
factors. Activation of leptomeningeal cells with the secre-
tion of several of the proteins listed above is also possible.
CFS syndromes may be initiated by unknown factors that
activate these cells, or they may activate anti-inflamma-
tory and innate immune defenses as a result of the origi-
nal insult. These possibilities may be addressed in future
studies and by comparison of the proteomes from CFS
subjects with different durations or patterns of illness.
Several novel proteins were identified. These included
Dickkopf-3 [88], disco-interacting protein 2 [Drosophila]
(DIP2) [102], neuronal PAS domain protein 2 (seasonal
affective disorder – related) [103], additional sex combs –
like protein 1 (ASXL1) [104], and neuroglobin [23]. Sev-
eral were represented by only a single, highly selective
peptide ' [see Additional file 1]'. Keratins 5, 6c, 6e, 14, 16,
and 17 were the largest single protein family to be newly
described [96-99].
No proteins were significantly associated with the good
health of the HC subjects.
Conclusion
This pilot investigation demonstrated that the CFS, PGI
and FM subjects had a significant overlap between their
syndromes. Despite the differences in their original case
designations, they had very similar responses on ques-
tionnaire, quality of life and nociceptive measures. Again,
despite the differences in the diagnostic label applied to
them for study entry, their cerebrospinal fluid proteomes
demonstrated reproducible constituents. The CFS –BMC Neurology 2005, 5:22 http://www.biomedcentral.com/1471-2377/5/22
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related proteome was essentially the same for the two
independent CFS cohorts. The proteome was remarkable
for the number of proteins associated with protein mis-
folding and cerebrovascular amyloidosis syndromes.
These included gelsolin, amyloid β protein (APLP1), Ig λ,
C3, C4, chromogranin B, α2-macroglobulin and α-1-anti-
chymotrypsin antiproteases, the heme and iron scaven-
gers haptoglobin, hemopexin, and orosomucoid 2,
angiogenic and antiangiogenic prohormones such as
autotaxin and PEDF, and the structural proteins gelsolin,
BEHAB and keratin 16. Their presence in the CFS – asso-
ciated proteome suggested a potential pathophysiological
link. We propose the hypothesis that CFS may be a nonle-
thal, protein – misfolding, cerebrovascular amyloidosis –
like syndrome.
An objective statistical model was derived to predict CFS
status based only on the proteomic detection of keratin
16, α-2-macroglobulin, orosomucoid 2, autotaxin, and
pigment epithelium-derived factor. This is the first predic-
tive model of CFS to be based only on objective data. This
legitimizes our hypothesis that a common central nervous
system pathophysiology was present in the CFS spectrum
of illnesses. Despite the many combinations of "labels"
(e.g. CFS, FM, PGI) applied to each subject (figure 1), only
one, consistent CFS – related proteome was obtained
from the two independent sets of subjects (table 3). Indi-
vidual proteins or their patterns of detection ("biosigna-
tures" [14,18-20]) may prove to be valuable biomarkers
in diagnostic assays. These assays may gauge disease sever-
ity, dynamic variations in symptomatology, and longitu-
dinal alterations with age or treatments. Given the
continued controversy over whether CFS and its allied
syndromes are legitimate medical conditions, our pro-
teomic model provides initial objective evidence for the
legitimacy of CFS as a distinct neurological disease.
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